A clinical study to evaluate the efficacy and safety of MK0633 in patients with Chronic Obstructive Pulmonary Disease (COPD).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
266
MK0633 100mg capsules qd for a 12-wk treatment period.
MK0633 100mg Pbo capsules for a 12-wk treatment period
Pulmonary function test data
Time frame: Measured over 12 weeks
Overall daytime symptoms score, total daily beta agonist use, and Chronic Respiratory Disease Questionnaire (CRQ) score
Time frame: Measured over 12 weeks of treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.